Biotech company 10x Genomics filed two lawsuits against rival Illumina in Delaware federal court on Tuesday, accusing ...

Genomics has administered a double dose of litigation to Illumina, joining with separate partners in a pair of federal lawsuits accusing the sequencing giant of infringing on nine patents related to ...

The Broad Institute gene-sequencing lab used Roche equipment to read infants’ DNA genomes in less than four hours, cutting an hour off the previous Guinness World Record.

On October 21, 10x Genomics, Inc. and Prognosys Biosciences, Inc. filed a complaint for patent infringement against Illumina, ...

Illumina is rated a BUY as it drives growth with AI, multiomics, and strategic acquisitions. Click here to read my earnings preview of ILMN stock.

The global next generation sequencing (NGS) market is expected to register a robust CAGR of around 15% over the next five years. This growth is primarily driven by the rising adoption of precision ...

Having examined the options trading patterns of Illumina, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance Trading volume ...

SAN DIEGO, Oct. 17, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced that GeneDx, a leader in genetic testing for rare diseases, is piloting Illumina's emerging constellation mapped read ...